Transitioning from usual care to biomarker-based personalized and precision medicine in heart failure: call for action

被引：27

作者：

Bayes-Genis, Antoni ^{[1
,2
,3
]}

Voors, Adriaan A. ^{[4
]}

Zannad, Faiez ^{[5
]}

Januzzi, James L. ^{[6
]}

Richards, A. Mark ^{[7
,8
]}

Diez, Javier ^{[3
,9
,10
]}

机构：

[1] Hosp Badalona Germans Trias & Pujol, Heart Inst, Badalona, Spain

[2] Autonomous Univ Barcelona, Dept Med, Barcelona, Spain

[3] Inst Salud Carlos III, CIBERCV, Madrid, Spain

[4] Univ Groningen, Univ Med Ctr Groningen, Dept Cardiol, Groningen, Netherlands

[5] Univ Lorraine, CHRU Nancy, F CRIN INI CRCT, INSERM,CIC1433, Nancy, France

[6] Massachusetts Gen Hosp, Cardiol Div, Boston, MA 02114 USA

[7] Univ Otago, Christchurch Heart Inst, Christchurch, New Zealand

[8] Natl Univ Singapore, Cardiovasc Res Inst, Singapore, Singapore

[9] Univ Navarra, Program Cardiovasc Dis, Ctr Appl Med Res, Pamplona, Spain

[10] Univ Navarra, Univ Clin, Dept Cardiol & Cardiac Surg, Pamplona, Spain

来源：

EUROPEAN HEART JOURNAL | 2018年 / 39卷 / 30期

关键词：

HOSPITALIZATION; PREVALENCE; PREDICTION; MORTALITY; DIAGNOSIS; COMMUNITY; SCORE; ESC;

D O I：

10.1093/eurheartj/ehx027

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

[No abstract available]

引用

页码：2793 / +

页数：7

共 31 条

[1] Biomarker-Guided Adaptive Trial Designs in Phase II and Phase III: A Methodological Review [J].

Antoniou, Miranta ;

Jorgensen, Andrea L. ;

Kolamunnage-Dona, Ruwanthi .

PLOS ONE, 2016, 11 (02)

[2] Long Noncoding RNAs in Cardiovascular Pathology, Diagnosis, and Therapy [J].

Bar, Christian ;

Chatterjee, Shambhabi ;

Thum, Thomas .

CIRCULATION, 2016, 134 (19) :1484-1499

[3] Multiple biomarker strategies for risk stratification in heart failure [J].

Bayes-Genis, Antoni ;

Ordonez-Llanos, Jordi .

CLINICA CHIMICA ACTA, 2015, 443 :120-125

[4] Heart Failure [J].

Braunwald, Eugene .

JACC-HEART FAILURE, 2013, 1 (01) :1-20

[5] Prevalence of chronic heart failure in Southwestern Europe: the EPICA study [J].

Ceia, F ;

Fonseca, C ;

Mota, T ;

Morais, H ;

Matias, F ;

de Sousa, A ;

Oliveira, AG .

EUROPEAN JOURNAL OF HEART FAILURE, 2002, 4 (04) :531-539

[6] Adverse mortality effect of central sympathetic inhibition with sustained-release moxonidine in patients with heart failure (MOXCON) [J].

Cohn, JN ;

Pfeffer, MA ;

Rouleau, J ;

Sharpe, N ;

Swedberg, K ;

Straub, M ;

Wiltse, C ;

Wright, TJ .

EUROPEAN JOURNAL OF HEART FAILURE, 2003, 5 (05) :659-667

[7] Clinical trials update: RENEWAL (RENAISSANCE and RECOVER) and ATTACH [J].

Coletta, AP ;

Clark, AL ;

Banarjee, P ;

Cleland, JGF .

EUROPEAN JOURNAL OF HEART FAILURE, 2002, 4 (04) :559-561

[8]

Daniels LB, 2014, FUTUR CARDIOL, V10, P525, DOI [10.2217/fca.14.36, 10.2217/FCA.14.36]

[9] Insulin-Like Growth Factor-Binding Protein-7 as a Biomarker of Diastolic Dysfunction and Functional Capacity in Heart Failure With Preserved Ejection Fraction Results From the RELAX Trial [J].

Gandhi, Parul U. ;

Gaggin, Hanna K. ;

Redfield, Margaret M. ;

Chen, Horng H. ;

Stevens, Susanna R. ;

Anstrom, Kevin J. ;

Semigran, Marc J. ;

Liu, Peter ;

Januzzi, James L., Jr. .

JACC-HEART FAILURE, 2016, 4 (11) :860-869

[10] Established and Emerging Roles of Biomarkers in Heart Failure Clinical Trials [J].

Ibrahim, Nasrien E. ;

Gaggin, Hanna K. ;

Konstam, Marvin A. ;

Januzzi, James L., Jr. .

CIRCULATION-HEART FAILURE, 2016, 9 (09)

← 1 2 3 4 →